Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
- Gina Ma,
- Yi Wang,
- Tahmeena Ahmed,
- Ann Leslie Zaslav,
- Laura Hogan,
- Cecilia Avila
- iCell Gene Therapeutics LLC,
- Stony Brook Medicine,
- Stony Brook University,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 42-44 (3 pages)Journal (Volume, Issue Number)
Leukemia Research Reports (Volume 9)Publication milestones
- Published - 2018
Publication status
Published - 2018
ISSN
2213-0489Publication IDs
- Scopus: 85045192515
Publication metrics
Metrics
SciVal
citations
4
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
SciVal
FWCI
0.33
SciVal
Author count
8
SciVal
Paper percentile
62
PlumX, opens in new tab
Captures
21
Citation count
22
